Fortrea (FTRE) Stock Price, News & Analysis

Company Overview

Fortrea Holdings Inc. (NASDAQ:FTRE) is a global contract research organization (CRO) that provides clinical development and related services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors as they plan, manage and evaluate clinical studies designed to bring new medicines and therapies to market.

Fortrea’s services span clinical trial management, patient recruitment and engagement, data management, biostatistics, medical monitoring, regulatory support and clinical pharmacology. Its work covers a range of therapeutic areas and can extend across early- through late-stage development, post-approval studies and real-world evidence programs.

The company was formed through the separation of Labcorp’s clinical development business and began operating as an independent publicly traded company in July 2023. Fortrea serves clients through operations and clinical research networks across multiple international markets, supporting studies conducted in North America, Europe, Asia-Pacific and other regions.

Key Stats

• Today's Range: $19.62 to $20.61
• 50-Day Range: $16.79 to $20.70
• 52-Week Range: $8.31 to $21.39
• Volume: 2.69 million shs
• Average Volume: 1.11 million shs
• Market Capitalization: $1.90 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Hold

Fortrea Stock Analysis - MarketRank™

Fortrea scored higher than 55% of companies evaluated by MarketBeat, and ranked 430th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Fortrea has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on no strong buy ratings, 5 buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Fortrea has a consensus price target of $22.00, representing about 10.2% upside from its current price of $19.97.

Amount of Analyst Coverage

Fortrea has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 24.71%

Earnings Growth

Earnings for Fortrea are expected to grow by 24.71% in the coming year, from $0.85 to $1.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fortrea is -21.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fortrea is -21.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Fortrea has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Fortrea has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.64% of the float of Fortrea has been sold short.

Short Interest Ratio / Days to Cover

Fortrea has a short interest ratio ("days to cover") of 11.67, which indicates bearish sentiment.

Change versus previous month

Short interest in Fortrea has recently increased by 3.79%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Fortrea does not currently pay a dividend.

Dividend Growth

Fortrea does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.38

News Sentiment

Fortrea has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Fortrea this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for FTRE on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

2 people have added Fortrea to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Fortrea insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,917,635.00 in company stock.

Percentage Held by Insiders

0.73% of the stock of Fortrea is held by insiders.

Percentage Held by Institutions

Fortrea has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 9/16/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:FTRE
• CIK: 1965040
• Web: www.fortrea.com
• Phone: 877-495-0816
• Fax: N/A
• Employees: 14,300
• Year Founded: 2023

Price Target and Rating

• Average Price Target for Fortrea: $22.00
• High Price Target: $26.00
• Low Price Target: $16.00
• Potential Upside/Downside: +10.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 23.49
• P/E Growth: 0.42
• Net Income: -$986.20 million
• Net Margins: -3.18%
• Pretax Margin: -2.91%
• Return on Equity: 10.72%
• Return on Assets: 2.17%

Debt

• Debt-to-Equity Ratio: 1.98
• Current Ratio: 0.96
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $2.72 billion
• Price / Sales: 0.70
• Cash Flow: $11.35 per share
• Price / Cash Flow: 1.76
• Book Value: $6.10 per share
• Price / Book: 3.27

Miscellaneous

• Outstanding Shares: 95,100,000
• Free Float: 94,406,000
• Market Cap: $1.90 billion
• Optionable: Optionable
• Beta: 1.97